Hem#265 Rar May 2026

This paper highlights a novel method that combines the ligand-binding domain (LBD) of RAR with the trafficking machinery of the GR, creating a chimeric receptor that moves from the cytoplasm to the nucleus upon ligand binding. 2. Methodology: Design of the GR-RAR Chimera

Are you looking to focus on the of RAR or the technical design of the chimera? Hem#265 rar

Nuclear receptors, such as the Retinoic Acid Receptor (RAR), are critical in gene regulation but often difficult to monitor in real-time within living cells. This paper explores the development of a GR-RAR chimeric protein, which fuses the nuclear/cytoplasmic translocation properties of the Glucocorticoid Receptor (GR) with the ligand responsiveness of RAR. This chimeric receptor provides a robust, in vivo, real-time translocation assay to detect physiological concentrations of RAR ligands, providing a powerful tool for ligand identification and subcellular trafficking analysis. 1. Introduction This paper highlights a novel method that combines

The GR-RAR chimera is a powerful tool for discovering novel RAR ligands and analogues. It improves upon standard assays that exclusively measure gene activation potential, as this system visualizes the receptor's subcellular trafficking. This technique offers significant advantages in studies exploring ligand-induced receptor dynamics. 5. Conclusion Nuclear receptors, such as the Retinoic Acid Receptor

Development and Application of a Glucocorticoid/Retinoic Acid Receptor (GR-RAR) Chimera for In Vivo Translocation Assays

The chimeric receptor provides a dramatic and easily monitored visual indicator of RAR ligand presence in the cellular environment.

The translocation from cytoplasm to nucleus is observable in living cells, allowing for kinetic studies.